SCHEMBL7678955

SCHEMBL7678955

Cc1csc2c(NC(C)(C)C)nc(Cl)nc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PRKCI P41743 6/20 0.36
CYP1A2 P05177 1/20 0.34
PDE4A P27815 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPC1 O15118 2/20 0.34
TNKS O95271 1/20 0.33
PARP1 P09874 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
ESR1 P03372 1/20 0.33
AXL P30530 2/20 0.32
INSR P06213 1/20 0.32
KDM4E B2RXH2 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RAB9A P51151 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31
YTHDC1 Q96MU7 1/20 0.31
PDPK1 O15530 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7685322 0.85 PRKCI (0.34) PRKCITNKSPARP1TNKS2ESR1
SCHEMBL19933189 0.82 YTHDC1 (0.44) SMN1; SMN2PRKCIESR1AXLINSR
SCHEMBL3960807 0.81 PRKCI (0.40) LMNASMN1; SMN2PRKCIESR1AXL
SCHEMBL7686027 0.81 PDE7A (0.35) LMNASMN1; SMN2CYP1A2PDE4ACYP2C19
SCHEMBL7679000 0.81 PRKCI (0.41) PRKCITNKSPARP1TNKS2ESR1
SCHEMBL7685359 0.79 KMT2A (0.35) LMNASMN1; SMN2CYP1A2PDE4ACYP2C19
SCHEMBL7683422 0.78 PRKCI (0.36) SMN1; SMN2PRKCIESR1AXLINSR
SCHEMBL7677294 0.78 PRKCI (0.44) LMNAPRKCINPC1ESR1AXL
SCHEMBL7677193 0.78 PRKCI (0.40) SMN1; SMN2PRKCIESR1AXLINSR
SCHEMBL7678911 0.76 PRKCI (0.48) PRKCIYTHDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6339089-B2 ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT FUJIREBIO INC. (JP) 2002-01-15 US disclosed
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) 2001-07-05 US disclosed
EP-0899263-A2 Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration Fujirebio Inc. (JP) 1999-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME CYP11B2, CYP11B1, OAT LMNA 1397/4885SMN1; SMN2 2359/4885PRKCI 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.